Vertex delivered Q4 2025 revenue of $3190000000, up 10% year-over-year, with GAAP net income of $1191100000 and diluted EPS of $4.65. Growth was driven by TRIKAFTA/KAFTRIO and ALYFTREK, along with contributions from CASGEVY and JOURNAVX.

Vertex delivered solid earnings in Q3 2025, with net income surpassing $1 billion and revenue growing 11% YoY. The company saw early momentum from JOURNAVX and CASGEVY while maintaining leadership in cystic fibrosis treatments.

Vertex Pharmaceuticals delivered a strong second quarter in 2025, with total revenue increasing by 12% to $2.96 billion, primarily due to the continued performance of cystic fibrosis therapies and early contributions from new product launches like ALYFTREK, JOURNAVX, and CASGEVY. The company also reported significant improvements in GAAP and non-GAAP net income compared to the prior year, which had been impacted by a large acquisition-related expense.

Vertex delivered Q1 2025 revenue of $2.77B and adjusted EPS of $4.06, with continued momentum in CF therapies and early launches of ALYFTREK and JOURNAVX; GAAP net income declined due to a $379M impairment.

Vertex Pharmaceuticals reported strong Q4 2024 results with a 16% increase in product revenue, reaching $2.91 billion, driven by the continued performance of TRIKAFTA/KAFTRIO. However, net income declined slightly due to increased R&D and SG&A expenses.

Vertex Pharmaceuticals reported a 6% increase in product revenue to $2.65 billion for Q2 2024, driven by TRIKAFTA/KAFTRIO. The company raised its full-year product revenue guidance to $10.65 to $10.85 billion. Key advancements include FDA acceptance of NDA for vanzacaftor triple in CF and suzetrigine for acute pain.

Vertex Pharmaceuticals reported a 14% increase in product revenue to $2.49 billion for Q2 2023, driven by strong uptake of TRIKAFTA/KAFTRIO internationally and continued performance in the U.S. The company raised its full-year 2023 revenue guidance to $9.7 to $9.8 billion.